Recursion Pharmaceuticals

Recursion Pharmaceuticals

RXRX· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock -39.5% in FY2025

Najat Khan is the CEO of Recursion Pharmaceuticals and was paid $5.3M in FY2025 (Dec), down 42%.

Pay$100 in the stock at the end of FY23 → $41
CEO pay is from each Recursion Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives3

See all
  1. 1Chris Gibson, Ph.D.FY2025
  2. 2Najat KhanFY2025
  3. 3Ben TaylorFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Recursion Pharmaceuticals paid its 3 named executives $16.3M in total in FY2025 (Dec). CEO Najat Khan was paid $5.3M of that.

Name
Chris Gibson, Ph.D.former Chief Executive Officer and President and current Chair of the Board
Najat Khancurrent Chief Executive Officer and PresidentNot disclosed
Ben TaylorChief Financial OfficerNot disclosed

of each named executive, from the Summary Compensation Table of each proxy.

Peers16

See all

The FY2025 (Dec) proxy of Recursion Pharmaceuticals names 16 peer companies for pay. Pay versus performance data of Recursion Pharmaceuticals for that year is not on file, so it has no rank.

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Activity

  1. Pay
    Recursion Pharmaceuticals CEO pay fell 42% to $5.3M. The stock fell 39% in FY2025 (Dec).
    DEF 14A
  2. Pay
    Recursion Pharmaceuticals President pay rose 13% to $9.6M. The stock fell 39% in FY2025 (Dec).
    DEF 14A
  3. Pay
    Recursion Pharmaceuticals CFO pay fell 84% to $1.3M. The stock fell 39% in FY2025 (Dec).
    DEF 14A
  4. Pay
    Recursion Pharmaceuticals President pay rose 21% to $5.9M. The stock fell 31% in FY2024 (Dec).
    DEF 14A
  5. Pay
    Recursion Pharmaceuticals President pay rose 364% to $2.8M. The stock fell 55% in FY2022 (Dec).
    DEF 14A
  6. Pay
    Recursion Pharmaceuticals Former CFO pay rose 12% to $5.0M. The stock fell 31% in FY2024 (Dec).
    DEF 14A
  7. Pay
    Recursion Pharmaceuticals Former CFO pay rose 310% to $2.1M. The stock fell 55% in FY2022 (Dec).
    DEF 14A
  8. Pay
    Recursion Pharmaceuticals Chief Medical Officer pay fell 55% to $1.9M. The stock fell 31% in FY2024 (Dec).
    DEF 14A
  9. Pay
    Recursion Pharmaceuticals President pay rose 838% to $6.3M. The stock fell 55% in FY2022 (Dec).
    DEF 14A
  10. Pay
    Recursion Pharmaceuticals President pay rose 76% to $4.9M. The stock rose 28% in FY2023 (Dec).
    DEF 14A
  11. Pay
    Recursion Pharmaceuticals Former Chief Corporate Development Officer pay rose 59% to $2.8M. The stock rose 28% in FY2023 (Dec).
    DEF 14A
  12. Pay
    Recursion Pharmaceuticals Former Chief Corporate Development Officer pay rose 157% to $1.8M. The stock fell 55% in FY2022 (Dec).
    DEF 14A
  13. Pay
    Recursion Pharmaceuticals Former CFO pay rose 116% to $4.5M. The stock rose 28% in FY2023 (Dec).
    DEF 14A
  14. Pay
    Recursion Pharmaceuticals President pay rose 36% to $8.6M. The stock rose 28% in FY2023 (Dec).
    DEF 14A

Filings6

See all
Proxy statementDEF 14AApr 30, 2026FY2025
Annual report10-KFeb 25, 2026FY2025
Proxy statementDEF 14AApr 28, 2025FY2024
Annual report10-KFeb 28, 2025FY2024
Proxy statementDEF 14AApr 23, 2024FY2023
Annual report10-KFeb 29, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data